Deal Announcements
Ankasa Accepts Series A Venture Capital Funds
Wednesday, June 24, 2015 5:32:00 AM PDT | VentureDeal
La Jolla, California -- Pharmaceutical technology company Ankasa Regenerative Therapeutics (no website) received $8.5 million in the first tranche of its Series A funding round.
Ankasa is developing pharmaceutical preparations for reactivation of stem cells for organ and tissue regrowth, tissue repair and healing.
The company's products aimed to improve tissue healing by exploiting the potential of WNT stem cell activators.
Avalon Ventures led the round, which included Correlation Ventures and other strategic investors.
The company said it will use the funding to develop a proprietary therapy involving WNT3A for spinal fusion surgery patients.
Email Page | 
Print Page